drugset / Trial / NCT04869579

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579

Phase 2 Unknown 100 enrolled CHRISTUS Health Pharco Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Given its anti-viral, anti-oxidative, immune-enhancing, cytokine-modulating, and anticoagulant properties, the investigators hypothesize that Selenium infusion at supranutritional doses for moderately-ill, severely-ill, and critically-ill COVID-19 patients will prevent further clinical deterioration thus decreasing overall mortality and improving survival. To test this hypothesis, a prospective, single-center, phase II trial is proposed to assess the efficacy of Selenium in hospitalized adult patients with moderate, severe, and critical COVID-19 infections.

Timeline

Start
2021-08-15
Primary completion
2021-11-15
Completion
2021-12-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Selenium Other / unclassified 1000 ug Other

Indications